G2GBIO Inc. (KOSDAQ:456160)

South Korea flag South Korea · Delayed Price · Currency is KRW
235,000
+2,000 (0.86%)
At close: Sep 23, 2025
171.68%
Market Cap 1.13T
Revenue n/a
Net Income n/a
Shares Out 5.37M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 646,391
Average Volume 544,646
Open 235,000
Previous Close 233,000
Day's Range 228,500 - 248,000
52-Week Range 82,700 - 238,500
Beta n/a
RSI 65.99
Earnings Date n/a

About G2GBIO

G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company’s pipeline products includes GB-5001, GB-5001A, and GB-5112 for the treatment of alzheimer’s disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal c... [Read more]

Industry Pharmaceutical Preparations
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456160
Full Company Profile

News

There is no news available yet.